RxDoctor Payments Data

Candice Coleman, NP

Adult Health · Jackson, MSNPI 1073912366

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 112 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations.

$3,160in general payments, 2019–2025

Across 112 payments — averaging $28.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$745
  • AstraZeneca$513
  • Gilead$506
  • Boehringer Ingelheim$272
  • Abbott$262
  • Bayer$188
  • plus $675 from 10 others

What the payments were for

  • Food & beverage$3,160100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,160 in reported general payments places this provider in the 80th percentile of 93 adult health providers in Mississippi.

See all adult health providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,488
Medicare patients
21
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin27$40,044
FarxigaDapagliflozin Propanediol13$16,314
Synjardy XrEmpagliflozin/Metformin Hcl16$10,976
Celecoxib41$2,253
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,195
Atorvastatin Calcium186$1,801
Amlodipine Besylate164$1,083
Levothyroxine Sodium58$769
Omeprazole47$642
Hydralazine Hcl39$589
Albuterol Sulfate HfaAlbuterol Sulfate16$581
Gabapentin61$569
Esomeprazole Magnesium13$428
Pravastatin Sodium34$423
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide13$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$272$51,02043 claims
AstraZenecaFarxiga$513$16,31413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 93 adult health providers in Mississippi.

Other adult health in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →